FDA approves Merck’s RSV shot for babies despite 11.71% serious adverse reactions
The following information is from Children’s Health Defense. The FDA has approved Merck’s RSV antibody injection for newborns and infants, to be marketed under the name Enfanzia. The one-time shot, known scientifically as clesrovimab, is Merck’s direct competitor to Sanofi and […]
FDA approves Merck’s RSV shot for babies despite 11.71% serious adverse reactions Read More »